中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

24 records (took 0.029 seconds)

    정족수 감지 억제 활성 및 항균 활성을 갖는 항균용 조성물
    13.
    发明公开
    정족수 감지 억제 활성 및 항균 활성을 갖는 항균용 조성물 有权
    具有感应抑制活性和抗菌活性的新型抗微生物感染

    公开(公告)号：KR1020130120635A

    公开(公告)日：2013-11-05

    申请号：KR1020120043678

    申请日：2012-04-26

    Applicant: 울산대학교 산학협력단 ,  세종대학교산학협력단

    Inventor： 김양수 ,  임동렬 ,  구영원

    IPC: A01N43/40 ,  A01N29/04 ,  A01P1/00

    CPC classification number: A01N43/38 ,  A01N25/12 ,  A23L3/34635 ,  A61K31/404 ,  A61L2420/06

    Abstract: The present invention relates to an antimicrobial composition which contains a specific compound or salt thereof as an active component. The specific compound or salt thereof is capable of being coated on antimicrobial drugs, health food, and artificial implants including central venous catheters, artificial joints, and artificial valves for preventing the generation of a bio film on the artificial implants and directly controlling the generation of bacterial by having antimicrobial activity. The antimicrobial composition is capable of being useful as a coating composition for preventing the infection on the artificial implants.

    Abstract translation: 本发明涉及含有作为活性成分的特定化合物或其盐的抗微生物组合物。 特定的化合物或其盐能够被涂覆在抗菌药物，保健食品和包括中心静脉导管，人造关节和人造瓣膜的人造植入物上，用于防止在人造植入物上产生生物膜并直接控制 细菌具有抗菌活性。 抗微生物组合物能够用作防止人造植入物感染的涂料组合物。

    셀레노펜-접합 방향족 화합물을 포함하는 항암제
    14.
    发明公开
    셀레노펜-접합 방향족 화합물을 포함하는 항암제 有权
    含有SELENOPHENE-FUSED AROMATIC COMPOUNDS的反应剂试剂

    公开(公告)号：KR1020130064018A

    公开(公告)日：2013-06-17

    申请号：KR1020120139440

    申请日：2012-12-04

    Applicant: 세종대학교산학협력단 ,  사회복지법인 삼성생명공익재단

    Inventor： 임동렬 ,  남도현 ,  두베이라스미 ,  이한근

    IPC: C07D421/06 ,  C07D421/14 ,  A61K31/555 ,  A61P35/00

    Abstract: PURPOSE: An anticancer agent containing a selenophene-conjugated aromatic compound is provided to easily and cheaply obtain the selenophene-conjugated aromatic compound. CONSTITUTION: A selenophene-conjugated aromatic compound is denoted by chemical formula 1, 2, and 3. An anticancer composition contains the selenophene-conjugated aromatic compound. A method for preparing the selenophene-conjugated aromatic compound comprises a step of reacting an MCBI(7-methoxy-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one) compound of chemical formula 1a and a selenium-containing aromatic compound of chemical formula 1b.

    Abstract translation: 目的：提供含有硒吩酚共轭芳香族化合物的抗癌剂，容易且廉价地得到硒吩衍生的芳香族化合物。 构成：硒酚共轭芳族化合物由化学式1,2和3表示。抗癌组合物含有硒吩酚共轭芳族化合物。 制备该硒代苯并咪唑化合物的方法包括使化学式1a的MCBI（7-甲氧基-1,2,9,9a-四氢环丙[c]苯并[e]吲哚-4-酮）化合物与 化学式1b的含硒芳香族化合物。

    살렌 전이금속 착화합물, 및 그 제조 방법
    15.
    发明授权
    살렌 전이금속 착화합물, 및 그 제조 방법 有权
    Salen过渡金属配合物及其制备方法

    公开(公告)号：KR101050273B1

    公开(公告)日：2011-07-19

    申请号：KR1020080116406

    申请日：2008-11-21

    Applicant: 세종대학교산학협력단

    Inventor： 임동렬 ,  박원철

    IPC: C07F15/06 ,  C07F15/02 ,  C07F15/04

    Abstract: 본 발명은 하기 의 살렌 전이금속 착화합물을 개시한다:


    상기 식에서,
    R
    1 , R
    2 , R
    3 , R
    4 , R
    5 , R
    6 , R
    7 , R
    8 , R
    9 , R
    10 , R
    11 , R
    12 , Ar
    1 , Ar
    2 , A , M, X, m 및 n은 발명의 상세한 설명을 참조한다.
    살렌

    Abstract translation: 本发明涉及到＆lt;公开的沙仑 - 过渡金属配合物;式1＆GT：

    수퍼옥사이드 디스뮤타아제 활성을 갖는 고리화합물
    16.
    发明授权
    수퍼옥사이드 디스뮤타아제 활성을 갖는 고리화합물 失效
    数量和质量

    公开(公告)号：KR100724586B1

    公开(公告)日：2007-06-04

    申请号：KR1020050120371

    申请日：2005-12-09

    Applicant: 세종대학교산학협력단 ,  재단법인서울대학교산학협력재단

    Inventor： 임동렬 ,  정진호 ,  박원철

    IPC: C07F13/00 ,  C07D471/00 ,  C07F1/08

    Abstract: A pentaaza macrocycle metal complex is provided to show excellent active oxygen scavenging capability with less toxicity and side effect, thereby being used as a pharmaceutical composition for preventing or treating diseases related to the active oxygen such as skin aging, cancer, dementia, and rheumatoid. The pentaaza macrocycle metal complex is represented by the formula(I), wherein each R1, R2, R3 and R4 is independently H or C1-4 alkyl substituted by a hetero cycle or an aromatic cycle, the hetero cycle and the aromatic cycle able to be substituted by at least one substituent selected from the group consisting of C1-4 alkoxy, halogen, nitro, cyano, hydroxy, carboxyl and amino, each R5 and R6 is independently C1-7 alkyl or the R5 and R6 form a ring by being bound by C3-5 alkylene, M is a divalent metal selected from the group consisting of Mn, Fe and Cu, and each X and Y is independently a halide anion selected from the group consisting of Cl, Br, I, ClO3, ClO2, ClO, BrO4, BrO3, BrO2, BrO, IO4, and IO3, an anion of an organocarboxylic acid selected from the group consisting of acetic acid, trifluoroacetic acid, citric acid, formic acid, maleic acid, oxalic acid, succinic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, ascorbic acid, malic acid, methane sulfonic acid, benzene sulfonic acid and para-toluene sulfonic acid, an anion of a nitrate or a bicarbonate, and carboxylate or phenolate linked to one of the R1 to R6, provided that at least one of the R1, R2, R3 and R4 is not H. The pharmaceutical composition for preventing and treating cancer, stroke, Parkinson's disease, Alzheimer's disease, myocardial infarction, diabetic vascular disorder, hyperlipidemia, acute inflammation, rheumatoid, alcoholic hepatitis, glaucoma, macular degeneration and diabetic retinopathy comprises the pentaaza macrocycle metal complex as an effective ingredient.

    Abstract translation: 本发明提供五氮杂大环金属络合物，其显示优异的活性氧清除能力，毒性和副作用较小，因此可用作预防或治疗与皮肤老化，癌症，痴呆和类风湿等活性氧有关的疾病的药物组合物。 五氮杂大环金属配合物由式（I）表示，其中每个R 1，R 2，R 3和R 4独立地为H或被杂环或芳环取代的C 1-4烷基，杂环和芳环可以 被至少一个选自C 1-4烷氧基，卤素，硝基，氰基，羟基，羧基和氨基的取代基取代，每个R 5和R 6独立地为C 1-7烷基或者R 5和R 6通过 M是选自Mn，Fe和Cu的二价金属，并且每个X和Y独立地是选自Cl，Br，I，ClO 3，ClO 2， ClO，BrO 4，BrO 3，BrO 2，BrO，IO 4和IO 3，选自乙酸，三氟乙酸，柠檬酸，甲酸，马来酸，草酸，琥珀酸，苯甲酸的有机羧酸的阴离子 ，酒石酸，富马酸，扁桃酸，抗坏血酸，苹果酸，甲磺酸，b 苯磺酸和对甲苯磺酸，硝酸盐或碳酸氢盐的阴离子以及与R1-R6之一连接的羧酸盐或酚盐，条件是R1，R2，R3和R4中的至少一个不是H. 用于预防和治疗癌症，中风，帕金森病，阿尔茨海默氏病，心肌梗塞，糖尿病血管病症，高脂血症，急性炎症，类风湿，酒精性肝炎，青光眼，黄斑变性和糖尿病性视网膜病的药物组合物包含五氮杂大环金属络合物作为有效 成分。

    펙테노톡신-2 유도체, 및 이를 포함하는 항암 조성물
    18.
    发明公开
    펙테노톡신-2 유도체, 및 이를 포함하는 항암 조성물 有权
    PTENTENOTOXIN-2衍生物和含有它的抗原剂

    公开(公告)号：KR1020130069463A

    公开(公告)日：2013-06-26

    申请号：KR1020120145699

    申请日：2012-12-13

    Applicant: 세종대학교산학협력단 ,  서울대학교산학협력단

    Inventor： 임동렬 ,  강헌중 ,  이동섭 ,  전보람 ,  신원섭

    IPC: C07D493/22 ,  A61K31/335 ,  A61P35/00

    Abstract: PURPOSE: A pectenotoxin-2 derivative with various useful physical properties is provided to be used as an anticancer agent or a precursor thereof. CONSTITUTION: A pectenotoxin-2 derivative is denoted by chemical formula 1. An anticancer composition contains the derivative and removes cancer cells in human body. The cancer cells include cancer cells of lung, colon, central nervous system, skin, ovary, kidney, breast, or stomach.

    Abstract translation: 目的：提供具有各种有用物理性质的果胶毒素-2衍生物作为抗癌剂或其前体。 构成：化学式1表示果胶毒素-2衍生物。抗癌组合物含有衍生物并去除人体中的癌细胞。 癌细胞包括肺，结肠，中枢神经系统，皮肤，卵巢，肾，乳腺或胃的癌细胞。

    셀레닐-치환된 방향족 알데하이드계 화합물의 신규 제조 방법
    19.
    发明公开
    셀레닐-치환된 방향족 알데하이드계 화합물의 신규 제조 방법 无效
    制备取代的芳族醛类化合物的新方法

    公开(公告)号：KR1020120125573A

    公开(公告)日：2012-11-15

    申请号：KR1020110042766

    申请日：2011-05-06

    Applicant: 세종대학교산학협력단 ,  사회복지법인 삼성생명공익재단

    Inventor： 임동렬 ,  남도현 ,  두베이라스미

    IPC: C07C391/02 ,  C07D317/46 ,  C07D211/80 ,  C07D491/06

    Abstract: PURPOSE: A manufacturing method of selenyl-substituted aromatic aldehyde-based compound is provided to obtain selenyl-sbustituted aromatic aldehyde-based compound with high yield while minimizing generation of byproduct of a reaction. CONSTITUTION: A manufacturing method of selenyl-substituted aromatic aldehyde-based compound indicated in chemical formula 4 comprises: a step of preparing a reaction mixture comprising diselenide compound represented by A-Se-Se-A, solvent and a reducing agent; and a step of adding and reacting aromatic aldehyde-based starting material and base into the reaction mixture. The equivalent ratio of the diselenide compound and the reducing agent in the reaction mixture is 1:1/3-3.

    Abstract translation: 目的：提供烯丙基取代的芳族醛基化合物的制备方法，以最大限度地产生反应副产物的产率，以高产率获得烯丙基取代的芳族醛基化合物。 构成：化学式4中所示的苯乙烯基取代的芳族醛基化合物的制造方法包括：制备包含由A-Se-Se-A表示的二硒化合物，溶剂和还原剂的反应混合物的步骤; 和将芳族醛类原料和碱加入反应混合物中的步骤。 反应混合物中二硒化合物和还原剂的当量比为1:1 / 3-3。

Patent Agency Ranking